Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Glucocorticoid Receptor Inhibitors	Relacorilant (CORT125134) Corticosterone AL082D06 (20S)-Protopanaxatriol Cortodoxone

Solubility

In vitro
Batch:

DMSO : 86 mg/mL (197.92 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 17 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.3mg/ml (9.90mM)	Taking the 1 mL working solution as an example, add 50 μL of 86 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.61mg/ml (1.40mM)	Taking the 1 mL working solution as an example, add 50 μL of 12.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	434.5	Formula	C₂₄H₃₁FO₆	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	76-25-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Glucocorticoid receptor
In vitro	Triamcinolone Acetonide significantly decreases the paracellular permeability of ECV304 cells and down-regulated ICAM-1 expression, consistent with immunocytochemical observations. This compound reverses the osmotic swelling of glial cells in retinas of the rat that is observed under various experimental conditions: in retinas isolated at 3 days after transient retinal ischemia, in retinas of eyes with lipopolysaccharide-induced ocular inflammation, and in control retinas in the presence of Ba^{2+^{(1 mM), H₂O₂ (200 mM), arachidonic acid (10 mM), or prostaglandin E2 (30 nM). It reduces GAG synthesis compared to control and IL-1 alone. This chemical increases GAG degradation. It increases media GAG content compared to control and IL-1 explants.}}
In vivo	Triamcinolone Acetonide (TAC), a synthetic glucocorticoid, induces cleft palate resulting from poor development of palatal shelves in mice. This compound inhibits the proliferation of mesenchymal cells and affects the differentiation of MEE cells into stratified squamous epithelia in the palatal shelves of rat embryos. It reduces lameness, edema, and concentration of synovial fluid protein after the second LPS injection in horse. This chemical also induces higher WBC counts and mepivacaine concentrations in synovial fluid, compared with results for Mepivacaine alone.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10971511/ [2] https://pubmed.ncbi.nlm.nih.gov/16144977/ [3] https://pubmed.ncbi.nlm.nih.gov/12875321/ [4] https://pubmed.ncbi.nlm.nih.gov/15133269/ [5] https://pubmed.ncbi.nlm.nih.gov/19046013/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-13)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07762170	RECRUITING	Back Pain Lower Back; Neck Pain; Radiculopathy Multiple Sites; Spinal Stenosis Cervicothoracic Region; Spinal Stenosis Lumbar; Failed Back Surgery Syndrome (FBSS); Sciatica; Intervertebral Disc Disorders With Radiculopathy, Lumbar Region; Spine Osteoarthritis	Igor Wilderman. MD	2026-07-30	PHASE4
NCT07719270	NOT_YET_RECRUITING	Trismus; Edema; Pain	Allama Iqbal Medical College	2027-01-01
NCT07540728	NOT_YET_RECRUITING	Sudden Hearing Loss	Eye & ENT Hospital of Fudan University	2026-04-20	PHASE2
NCT06401317	RECRUITING	Trapeziometacarpal Osteoarthritis	Université du Québec à Trois-Rivières	2025-11-04	PHASE2
NCT06748404	RECRUITING	Immunotherapy-related Pruritus	University of California, San Diego	2025-03-05	PHASE2
NCT07100145	NOT_YET_RECRUITING	Oral Lichen Planus	Ain Shams University	2026-01-01	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Triamcinolone Acetonide Glucocorticoid Receptor agonist

Chemical Structure

Molecular Weight: 434.5